<DOC>
	<DOCNO>NCT00175643</DOCNO>
	<brief_summary>It believe imiquimod 5 % cream potential effective treatment actinic keratoses . The purpose study evaluate duration effect topical imiquimod 5 % topical cream treatment actinic keratoses .</brief_summary>
	<brief_title>Safety Efficacy Imiquimod Applied Dose-Cycle Actinic Keratoses</brief_title>
	<detailed_description>This study ass safety efficacy imiquimod 5 % cream apply actinic keratoses head reduce size lesion . The objective analyze effect dose cycle respect complete clearance rate imiquimod 5 % cream apply 3 time per week 4 week 1 2 cycle . The complete clearance rate define proportion subject clinically visible AK lesion treatment area end cycle 1 end cycle 2 .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>At least 18 year age . Have total 4 8 clinically typical , discrete , nonhyperkeratotic , nonhypertrophic AK lesion locate within contiguous 25 cm2 treatment area ( bald scalp face , ) . Free significant finding ( e.g . tattoo ) potential application site area may impair examination treatment surround area . Willing eliminate tanning bed/sun parlor use duration study . Evidence clinically significant , unstable cardiovascular immunosuppressive , hematologic , hepatic , neurologic , renal , endocrine , collagenvascular , gastrointestinal abnormality disease . Any dermatological disease condition treatment surround area may exacerbate treatment imiquimod cause difficulty examination ( e.g . rosacea , psoriasis , atopic dermatitis , eczema ) . Confirmed SCC , BCC anywhere head . Share household person participate concurrent clinical study imiquimod treat imiquimod 5 % topical cream . Active chemical dependency alcoholism , assess investigator . Females pregnant , breastfeed consider become pregnant study . Females childbearing unwilling practice effective method contraception , define investigator duration study well one month completion . Received treatment , product procedure within designated time period prior prestudy visit list page 4 protocol ( Version 03 dd March 2003 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>actinic keratoses</keyword>
	<keyword>imiquimod</keyword>
	<keyword>pre-malignant</keyword>
	<keyword>squamous cell carcinoma</keyword>
	<keyword>immunosuppression</keyword>
</DOC>